Understanding genetic basis for resistance to TNF-induced lethal shock using new

使用新方法了解抵抗 TNF 诱导的致死性休克的遗传基础

基本信息

  • 批准号:
    7978153
  • 负责人:
  • 金额:
    $ 20.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-20 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mortality from toxic shock, caused by infective agents that trigger excessive synthesis of tumor necrosis factor (TNF) and other inflammatory molecules by macrophages, remains a major health problem. Here we describe for the first time resistance to lipopolysaccharide (LPS) and TNF-induced death in vivo of wild-derived mice of MSM strain, representing a new genetic model of resistance to toxic shock. The remarkable resistance of these mice to toxic shock is further emphasized by their lack of sensitivity to acute liver injury caused by the co-administration of TNF and D-galactosamine, a well-established in vivo model of endotoxic liver damage. In support of the in vivo resistance data, we show that primary MSM macrophages exhibit another phenotype in that they are resistant to TNF- or TLR-agonists-induced regulated necrosis ("necroptosis") but not apoptosis cell death in vitro. Based on these results, we hypothesize that the two traits are mechanistically linked and propose to examine the connection between necroptosis and toxic shock traits by means of genetic linkage analysis aimed at identification of the loci, which confer both traits. In further extension of the in vitro results, we discovered that TNF-mediated in vivo liver injury can be prevented by a specific inhibitor of a key necroptosis regulator, RIP1 kinase. In addition to cell death phenotype, we demonstrate that TNF synthesis by MSM macrophages is reduced and may also be influenced by RIP1 signaling in vivo. Based on our preliminary data, we suggest that RIP1 kinase is a mediator of acute toxic shock and may represent an important new target for therapeutic intervention. We propose to further characterize the scope of changes in in vitro MSM hepatocyte and macrophage responses to TLR agonists and TNF in order to better determine the cellular basis for MSM resistance to toxic shock. Overall, these studies may provide important new insights into mechanisms of both toxic shock in vivo and necroptotic RIP1 kinase signaling, which has also been implicated in other acute pathologies, such as stroke, myocardial infarction and brain trauma. PUBLIC HEALTH RELEVANCE: Mortality from toxic shock, caused by infective agents that trigger excessive synthesis of tumor necrosis factor (TNF) and other inflammatory molecules by macrophages remains a major health problem. In this proposal, using genetic analysis of resistance to toxic shock in the wild-derived mice, we will reveal novel mechanisms of control of inflammation and its magnitude.
描述(由申请人提供):中毒性休克导致的死亡,是由感染因子引发巨噬细胞过度合成肿瘤坏死因子(TNF)和其他炎症分子引起的,仍然是一个主要的健康问题。本研究首次描述了野生源性MSM小鼠对脂多糖(LPS)的抵抗和tnf诱导的体内死亡,代表了一种新的中毒性休克抵抗遗传模型。这些小鼠对中毒性休克的显著抵抗进一步强调了它们对TNF和d -半乳糖胺共同给药引起的急性肝损伤缺乏敏感性,d -半乳糖胺是一种成熟的内毒素肝损伤体内模型。为了支持体内耐药数据,我们发现原发MSM巨噬细胞表现出另一种表型,它们在体外对TNF-或tlr激动剂诱导的受调节的坏死(“坏死性坏死”)有耐药性,但对凋亡细胞死亡没有耐药性。基于这些结果,我们假设这两个性状存在机制联系,并建议通过遗传连锁分析来研究坏死性下垂和中毒性休克性状之间的联系,旨在鉴定赋予这两个性状的位点。在进一步扩展体外实验结果时,我们发现tnf介导的体内肝损伤可以通过一种关键坏死性坏死调节因子RIP1激酶的特异性抑制剂来预防。除了细胞死亡表型外,我们还证明MSM巨噬细胞的TNF合成减少,并且也可能受到体内RIP1信号的影响。根据我们的初步数据,我们认为RIP1激酶是急性中毒性休克的介质,可能是治疗干预的重要新靶点。我们建议进一步表征体外MSM肝细胞和巨噬细胞对TLR激动剂和TNF反应的变化范围,以便更好地确定MSM抗中毒性休克的细胞基础。总的来说,这些研究可能为体内中毒性休克和坏死性RIP1激酶信号传导的机制提供重要的新见解,RIP1激酶信号传导也涉及其他急性病理,如中风、心肌梗死和脑外伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander Poltorak其他文献

Alexander Poltorak的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander Poltorak', 18)}}的其他基金

Regulation of LPS-responses by ZBP1
ZBP1 对 LPS 反应的调节
  • 批准号:
    10389170
  • 财政年份:
    2021
  • 资助金额:
    $ 20.63万
  • 项目类别:
Regulation of LPS-responses by ZBP1
ZBP1 对 LPS 反应的调节
  • 批准号:
    10492757
  • 财政年份:
    2021
  • 资助金额:
    $ 20.63万
  • 项目类别:
Regulation of LPS-responses by ZBP1
ZBP1 对 LPS 反应的调节
  • 批准号:
    10840500
  • 财政年份:
    2021
  • 资助金额:
    $ 20.63万
  • 项目类别:
Regulation of LPS-responses by ZBP1
ZBP1 对 LPS 反应的调节
  • 批准号:
    10808282
  • 财政年份:
    2021
  • 资助金额:
    $ 20.63万
  • 项目类别:
Regulation of LPS-responses by ZBP1
ZBP1 对 LPS 反应的调节
  • 批准号:
    10686361
  • 财政年份:
    2021
  • 资助金额:
    $ 20.63万
  • 项目类别:
Activation of STING-mediated pathway(s) in T cells
T 细胞中 STING 介导的通路的激活
  • 批准号:
    9229505
  • 财政年份:
    2016
  • 资助金额:
    $ 20.63万
  • 项目类别:
Understanding genetic basis for resistance to TNF-induced lethal shock using new
使用新方法了解抵抗 TNF 诱导的致死性休克的遗传基础
  • 批准号:
    8073126
  • 财政年份:
    2010
  • 资助金额:
    $ 20.63万
  • 项目类别:
Hyper-Responsiveness to TLR Agonists in Wild Derived Mice
野生小鼠对 TLR 激动剂的过度反应
  • 批准号:
    7683460
  • 财政年份:
    2008
  • 资助金额:
    $ 20.63万
  • 项目类别:
Genetic Analysis of Inflammatory Responses in Wild Derived Mice
野生小鼠炎症反应的遗传分析
  • 批准号:
    10534173
  • 财政年份:
    2003
  • 资助金额:
    $ 20.63万
  • 项目类别:
Genetic Dissection of Lipopolysaccharide Response
脂多糖反应的基因剖析
  • 批准号:
    6840777
  • 财政年份:
    2003
  • 资助金额:
    $ 20.63万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 20.63万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了